Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
COGT

COGT - Cogent Biosciences, Inc. Stock Price, Fair Value and News

$33.95-1.38 (-3.91%)
Market Closed

Price Targets

COGT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

COGT Price Action

Last 7 days

-8.4%

Last 30 days

-8.7%

Last 90 days

-19.4%

Trailing 12 Months

365.7%

COGT RSI Chart

COGT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

COGT Valuation

Market Cap

5.5B

Price/Earnings (Trailing)

-16.75

Price/Sales (Trailing)

775.97

Price/Free Cashflow

-20.72

COGT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

COGT Fundamentals

COGT Revenue

Revenue (TTM)

7.9M

COGT Earnings

Earnings (TTM)

-328.9M

Earnings Growth (Yr)

-50.89%

Earnings Growth (Qtr)

-26.64%

COGT Profitability

Return on Equity

-51.69%

Return on Assets

-35.08%

Free Cashflow Yield

-4.83%

COGT Investor Care

Shares Dilution (1Y)

46.94%

Diluted EPS (TTM)

-2.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202026.5M23.9M23.2M7.9M
201910.6M12.0M11.0M22.5M
20188.8M8.3M8.1M9.7M
20170008.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Cogent Biosciences, Inc.

COGT
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target exon 17 mutations found within the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
 CEO
 WEBSITEcogentbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES138

Cogent Biosciences, Inc. Frequently Asked Questions

COGT is the stock ticker symbol of Cogent Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Mar 13 2026, market cap of Cogent Biosciences, Inc. is 5.51 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Mar 13 2026, COGT's PE ratio (Price to Earnings) is -16.75 and Price to Sales (PS) ratio is 775.97. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. COGT PE ratio will change depending on the future growth rate expectations of investors.